All In Biotech

NDA 205641 · Organon LLC

Asmanex Hfa

Mometasone Furoate · Inhalation

Last checked: Nov 19, 2026Latest source record: Aug 12, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Apr 25, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

251

94 Phase 3, 12 recruiting

FAERS reports

11,481

7,460 serious, 505 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2026.

ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. ( 1.1 ) Important limitations: Not indicated for the relief of acute bronchospasm. ( 1.1 ) 1.1 Treatment of Asthma ASMANEX ® HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use ASMANEX HFA is NOT indicated for the relief of acute bronchospasm.

Mechanism: Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ASMANEX HFA · MOMETASONE FUROATE 0.20MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • ASMANEX HFA · MOMETASONE FUROATE 0.05MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • ASMANEX HFA · MOMETASONE FUROATE 0.10MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mometasone Furoate" as an intervention, any sponsor and status, largest first.

All 251 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,099
  • drug ineffective968
  • asthma945
  • headache934
  • cough818
  • off label use797
  • fatigue700
  • pruritus652
  • gastrooesophageal reflux disease603
  • wheezing579
  • nausea578
  • hypersensitivity566

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200457
200556
200656
200791
2008150
2009122
2010145
2011143
2012145
201396
2014139
2015225
2016382
2017424
2018897
2019876
2020840
20211,051
20221,262
20231,238
20241,058
20251,079
2026949

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Asmanex HFA (Mometasone Furoate)

2024 spending

$4.1M

Beneficiaries

11,660

29,556 claims

Per beneficiary

$351

$8.11 per unit

View as table
YearSpending
2020$0
2021$1,120,111
2022$7,506,929
2023$7,543,027
2024$4,089,600

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 420 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.